Vaccine composition comprising recombinant protein for preventing swine Mycoplasma infection
Provided are a recombinant protein for producing a swine Mycoplasma infection-preventing vaccine composition, and a swine Mycoplasma hyopneumoniae and Mycoplasma hyorhinis infection-preventing vaccine composition including the recombinant protein. When the recombinant proteins for the vaccine production in accordance with the present disclosure are added to the swine Mycoplasma infection-preventing vaccine composition, the immune response to the swine Mycoplasma hyopneumoniae and swine Mycoplasma hyorhinis strain and the immune response to the P97 protein are increased. As a result, the present vaccine exhibits a defensive effect superior to an existing commercially available vaccine. Therefore, the recombinant proteins for the vaccine production according to the present disclosure and the vaccine compositions using the recombinant proteins may effectively prevent diseases caused by the Mycoplasma hyopneumoniae and Mycoplasma hyorhinis infection, especially, swine Mycoplasma-derived pneumonia and swine Mycoplasma-derived arthritis..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Europäisches Patentamt - (2019) vom: 31. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
HAHN TAE WOOK [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2019-12-31, Last update posted on www.tib.eu: 2024-03-06, Last updated: 2024-03-15 |
|---|
| Patentnummer: |
US10519199 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000025585 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000025585 | ||
| 003 | DE-627 | ||
| 005 | 20240315100422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000025585 | ||
| 035 | |a (EPA)US10519199 | ||
| 035 | |a (EPA)61163155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a HAHN TAE WOOK |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine composition comprising recombinant protein for preventing swine Mycoplasma infection |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2019-12-31, Last update posted on www.tib.eu: 2024-03-06, Last updated: 2024-03-15 | ||
| 520 | |a Provided are a recombinant protein for producing a swine Mycoplasma infection-preventing vaccine composition, and a swine Mycoplasma hyopneumoniae and Mycoplasma hyorhinis infection-preventing vaccine composition including the recombinant protein. When the recombinant proteins for the vaccine production in accordance with the present disclosure are added to the swine Mycoplasma infection-preventing vaccine composition, the immune response to the swine Mycoplasma hyopneumoniae and swine Mycoplasma hyorhinis strain and the immune response to the P97 protein are increased. As a result, the present vaccine exhibits a defensive effect superior to an existing commercially available vaccine. Therefore, the recombinant proteins for the vaccine production according to the present disclosure and the vaccine compositions using the recombinant proteins may effectively prevent diseases caused by the Mycoplasma hyopneumoniae and Mycoplasma hyorhinis infection, especially, swine Mycoplasma-derived pneumonia and swine Mycoplasma-derived arthritis. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BARATE KASHINATH ABHIJIT |4 aut | |
| 700 | 0 | |a KIM KI JU |4 aut | |
| 700 | 0 | |a SHIN WOO SUNG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2019) vom: 31. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/61163155/publication/US10519199A1?q=US10519199 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2019 |b 31 |c 12 | ||